No Data
No Data
HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
HC Wainwright & Co. analyst Yi Chen reinstates First Wave BioPharma (NASDAQ:FWBI) with a Neutral.
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion diagnostics for
First Wave BioPharma Is Maintained at Buy by Roth MKM
First Wave BioPharma Is Maintained at Buy by Roth MKM
Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36
Roth MKM analyst Jonathan Aschoff maintains First Wave BioPharma (NASDAQ:FWBI) with a Buy and lowers the price target from $40 to $36.
First Wave BioPharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 627.27% Roth MKM $40 → $36 Maintains Buy 01/03/2024 708.08% Roth MKM $11 → $40 Maintains Buy 09
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersBetter Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. Madrigal Pharmaceutical
No Data